Your browser is no longer supported. Please, upgrade your browser.
FIXX Homology Medicines, Inc. daily Stock Chart
FIXX [NASD]
Homology Medicines, Inc.
Index- P/E- EPS (ttm)-2.62 Insider Own0.20% Shs Outstand45.15M Perf Week-15.97%
Market Cap659.22M Forward P/E- EPS next Y-2.86 Insider Trans-92.60% Shs Float42.77M Perf Month-6.13%
Income-115.40M PEG- EPS next Q-0.76 Inst Own91.60% Short Float9.51% Perf Quarter-27.92%
Sales2.00M P/S329.61 EPS this Y-26.80% Inst Trans-3.88% Short Ratio9.04 Perf Half Y-19.61%
Book/sh5.02 P/B2.78 EPS next Y6.50% ROA-36.70% Target Price- Perf Year-28.88%
Cash/sh4.97 P/C2.81 EPS next 5Y-9.40% ROE-44.90% 52W Range11.05 - 24.00 Perf YTD-32.66%
Dividend- P/FCF- EPS past 5Y- ROI-42.50% 52W High-41.92% Beta-
Dividend %- Quick Ratio13.70 Sales past 5Y- Gross Margin- 52W Low26.15% ATR0.92
Employees195 Current Ratio13.70 Sales Q/Q100.00% Oper. Margin- RSI (14)40.98 Volatility7.36% 5.83%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.60% Profit Margin- Rel Volume0.71 Prev Close14.08
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume449.65K Price13.94
Recom1.50 SMA20-9.76% SMA50-6.11% SMA200-12.42% Volume317,600 Change-0.99%
Jun-25-20Resumed BofA/Merrill Buy $30
May-13-20Initiated RBC Capital Mkts Outperform $30
Mar-16-20Upgrade Oppenheimer Perform → Outperform $32
Feb-24-20Initiated Chardan Capital Markets Buy $34
Nov-01-19Initiated Oppenheimer Perform
Sep-10-19Initiated Robert W. Baird Outperform
Apr-12-19Initiated Evercore ISI Outperform
Feb-20-19Initiated H.C. Wainwright Buy $36
Jan-07-19Initiated Canaccord Genuity Buy $37
Sep-07-18Initiated B. Riley FBR Neutral $18.50
Jul-08-20 08:49AM  
Jun-29-20 10:49AM  
Jun-27-20 02:58PM  
May-26-20 02:11PM  
May-19-20 04:08PM  
May-12-20 08:00AM  
May-10-20 09:45AM  
May-07-20 04:05PM  
Apr-29-20 08:00AM  
Apr-03-20 09:44AM  
Mar-16-20 09:00AM  
Mar-14-20 09:14AM  
Mar-12-20 05:45PM  
04:10PM  
Mar-11-20 09:22AM  
Mar-03-20 12:30PM  
Feb-20-20 09:00AM  
Feb-17-20 10:06AM  
Feb-13-20 09:00AM  
Jan-31-20 11:52AM  
Jan-14-20 08:33AM  
Jan-13-20 02:30PM  
Jan-10-20 02:20PM  
Jan-01-20 08:01AM  
Dec-24-19 10:49AM  
Dec-18-19 10:23AM  
07:23AM  
Dec-17-19 04:01PM  
Dec-16-19 09:00AM  
Dec-13-19 02:44PM  
Dec-03-19 08:30AM  
Nov-26-19 03:00PM  
Nov-12-19 07:35PM  
04:09PM  
Nov-05-19 10:32AM  
Oct-28-19 08:07PM  
Oct-25-19 08:30AM  
Oct-21-19 08:30AM  
Sep-30-19 08:49AM  
Sep-27-19 07:37AM  
Sep-03-19 08:30AM  
Aug-08-19 04:15PM  
Aug-05-19 10:31AM  
Aug-01-19 08:30AM  
Jul-15-19 04:01PM  
Jun-27-19 04:01PM  
Jun-25-19 01:45PM  
Jun-17-19 07:05AM  
Jun-13-19 08:30AM  
Jun-10-19 08:30AM  
May-14-19 09:00AM  
May-13-19 05:55PM  
04:50PM  
04:15PM  
May-09-19 08:45PM  
08:30AM  
May-06-19 10:30AM  
May-02-19 08:00AM  
Apr-30-19 12:00PM  
Apr-15-19 01:05PM  
Apr-09-19 07:08PM  
Apr-08-19 04:10PM  
Apr-04-19 04:05PM  
07:00AM  
Apr-02-19 07:12AM  
Mar-19-19 08:39AM  
Mar-12-19 07:30AM  
07:13AM  
Mar-06-19 08:30AM  
Mar-01-19 05:38PM  
Jan-07-19 09:25AM  
08:30AM  
Dec-18-18 09:57AM  
Dec-16-18 11:16PM  
Nov-13-18 05:07PM  
04:16PM  
Nov-08-18 08:30AM  
Nov-07-18 07:30AM  
Oct-18-18 07:00AM  
Oct-01-18 08:30AM  
Aug-30-18 08:30AM  
Aug-21-18 05:31AM  
Aug-13-18 04:16PM  
Jul-16-18 04:01PM  
Jul-05-18 08:30AM  
Jun-25-18 07:30AM  
May-18-18 07:30AM  
May-14-18 04:24PM  
May-10-18 08:30AM  
Apr-30-18 12:40PM  
Apr-23-18 09:00AM  
Apr-03-18 12:47PM  
08:30AM  
Mar-27-18 04:23PM  
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Timothy PSee RemarksMar 17Sale13.011,31517,1090Mar 18 05:32 PM
Smith W BradfordCFO, Treasurer & SecretaryFeb 03Option Exercise0.6312,0007,57912,000Feb 05 04:06 PM
Smith W BradfordCFO, Treasurer & SecretaryFeb 03Sale16.1612,000193,8660Feb 05 04:06 PM
TZIANABOS ARTHURPresident & CEOFeb 03Sale16.1612,500202,02177,505Feb 05 04:05 PM
Flynn James EPossible Member of 10% GroupJan 30Sale15.45509,9707,879,0370Jan 31 04:17 PM
Flynn James EPossible Member of 10% GroupJan 29Sale15.458,857136,808509,970Jan 31 04:17 PM
Flynn James EPossible Member of 10% GroupJan 28Sale15.5165,8911,021,936518,827Jan 28 06:38 PM
Flynn James EPossible Member of 10% GroupJan 27Sale15.77193,3593,049,600584,718Jan 28 06:38 PM
Flynn James EPossible Member of 10% GroupJan 24Sale15.69380,2565,965,000778,077Jan 28 06:38 PM
Smith W BradfordCFO, Treasurer & SecretaryJan 02Option Exercise0.636,0003,7906,000Jan 03 05:32 PM
TZIANABOS ARTHURPresident & CEOJan 02Sale20.5012,500256,19190,005Jan 03 05:36 PM
Seymour AlbertChief Scientific OfficerJan 02Sale20.509,133187,216154,017Jan 03 05:33 PM
Smith W BradfordCFO, Treasurer & SecretaryJan 02Sale20.506,000122,9840Jan 03 05:32 PM
Flynn James EPossible Member of 10% GroupDec 24Sale21.95350,0007,682,5351,766,106Dec 27 07:09 PM
Flynn James EPossible Member of 10% GroupDec 23Sale21.83130,9792,859,1931,917,339Dec 23 07:57 PM
Flynn James EPossible Member of 10% GroupDec 20Sale21.5021,129454,2781,973,934Dec 23 07:57 PM
Flynn James EPossible Member of 10% GroupDec 19Sale21.6812,622273,5891,983,064Dec 23 07:57 PM
Smith W BradfordCFO, Treasurer & SecretaryDec 02Option Exercise0.646,0003,8406,000Dec 03 04:07 PM
Smith W BradfordCFO, Treasurer & SecretaryDec 02Sale16.216,00097,2660Dec 03 04:07 PM
TZIANABOS ARTHURPresident & CEODec 02Sale16.2512,500203,176102,505Dec 03 04:06 PM
Seymour AlbertChief Scientific OfficerDec 02Sale16.239,300150,970163,150Dec 03 04:05 PM
Smith W BradfordCFO, Treasurer & SecretaryNov 29Option Exercise0.646,0003,8406,000Dec 03 04:07 PM
Smith W BradfordCFO, Treasurer & SecretaryNov 29Sale16.006,00096,0000Dec 03 04:07 PM
TZIANABOS ARTHURPresident & CEONov 29Sale16.0412,500200,559115,005Dec 03 04:06 PM
Seymour AlbertChief Scientific OfficerNov 29Sale16.069,300149,390172,450Dec 03 04:05 PM
Gregory Richard J.DirectorNov 18Option Exercise0.0310,80632410,806Jan 29 06:43 PM